Accelerating Innovation Against Global Health Threats

Vaccines and infectious disease research remain among the most strategically important areas of clinical development. Emerging pathogens, antimicrobial resistance, pandemic preparedness and evolving vaccination strategies continue to reshape global healthcare priorities.

Discuss Your Program Submit an RFP

Home/Therapeutic Areas/Vaccines and Infectious Diseases

Overview

Integrated Expertise for Vaccines and Infectious Diseases

Guosa Life Sciences supports vaccine and infectious disease programs through integrated clinical operations, laboratory coordination, cold-chain logistics, pharmacovigilance, regulatory strategy and collaborative research networks.

Explore Solutions

Areas of Expertise

Where We Focus

Preventive VaccinesTherapeutic VaccinesEmerging Infectious DiseasesPandemic PreparednessHIVTuberculosisMalariaEbolaInfluenzaCOVID-19RSVNeglected Tropical Diseases

Specialized Capabilities

Purpose-Built for This Therapeutic Area

Cold-chain logistics
Clinical depots
Vaccine accountability
Laboratory coordination
Safety surveillance
Outbreak response
Community engagement
Global health partnerships

Why GLS

Depth Where It Matters

Our integrated enterprise combines global health experience, operational excellence and collaborative partnerships supporting vaccine development across diverse research environments.

Clinical Operations
Regulatory Affairs
Quality Assurance
Laboratory Services
Pharmacovigilance
Data and Biostatistics

The capability

What We Actually Do

We run vaccine and infectious disease programs across the lifecycle: early-phase immunogenicity and safety studies in healthy volunteers, and large field efficacy trials enrolling dispersed cohorts where case ascertainment determines whether the study reads out.

Three things determine delivery: the cold chain, the laboratory and the community. We manage controlled-temperature distribution to the last mile with documented excursion handling, coordinate immunogenicity workflows including titer assays and specimen chain of custody, and build community engagement and local-language consent before enrollment opens rather than after recruitment stalls.

Regulatory considerations

AVAREF pathways and WHO prequalification

Vaccines are the therapeutic area where African regulatory harmonization is most mature. AVAREF, established in 2006 from a joint review of a meningococcal conjugate vaccine application, assesses a multi-country clinical trial application in parallel across every participating authority and ethics committee, with a maximum of 60 days to outcome against up to a year for a single-country filing. Expedited and emergency pathways, developed through the Ebola response and used again for COVID-19 and mpox, have enabled recruitment within 10 to 15 days.

Eligibility for joint review should therefore shape country selection rather than follow it, and applications must be aligned across countries at submission or they revert to sequential national review. Beyond trial approval, programs intended for public-sector procurement face a second track: WHO prequalification remains the gateway to tendering with Gavi, UNICEF, the Global Fund and PEPFAR, and its evidence requirements belong in the protocol rather than in a post-readout remediation plan.

How an engagement runs

The Sequence

1. Design and country strategy

Candidate countries assessed against disease burden, site capability, cold chain reach and joint review eligibility.

2. Aligned submission

A single coordinated package prepared for parallel review, with national annexes that keep the study inside the joint pathway.

3. Activation and conduct

Site qualification, investigator training, cold chain and laboratory setup, community engagement and monitored recruitment.

4. Readout and follow-through

Immunogenicity and safety reporting, close-out, and support for prequalification and national registration where relevant.

What you receive

Deliverables

A country selection analysis with modeled activation timelines. A coordinated multi-country submission. A documented cold chain with excursion handling. Specimen chain-of-custody and recruitment reporting.

Evidence and context

The Research Behind This Work

Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.

The Future of Clinical Trials in Africa The Untapped Advantage

The Ecosystem